留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

1例重症患者抗感染个体化给药策略分析

石晓萍 吕迁洲 杨婉花 方洁

石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
引用本文: 石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
Citation: SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

The individualized anti-infective treatment strategy for a critically ill patient

  • 摘要: 目的 探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。 方法 临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗,通过分析其病理生理状况,运用治疗药物监测,协助临床医生制订个体化的给药方案。 结果 患者初始抗感染治疗方案效果不佳,临床药师根据患者的个体情况和血药浓度监测结果调整给药方案,患者的感染得到控制,病情好转。 结论 确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。
  • [1] Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-e55.
    [2] Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care:a standardised loading dose results in earlier therapeutic levels[J]. Intern Med J, 2012,42(1):23-29.
    [3] 万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志, 2012,30(11):641-646.
    [4] 桑德福. 热病:桑德福抗微生物治疗指南[M]. 范洪伟译. 44版.北京:中国协和医科大学出版社, 2014:96-109.
    [5] Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists[J]. Clin Biochem Rev, 2010,31(1):21-24.
    [6] van Hal SJ, Fowler VJ. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?[J]. Clin Infect Dis, 2013,56(12):1779-1788.
    [7] Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
    [8] Rostas SE, Kubiak DW, Calderwood MS. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity[J]. Clin Ther, 2014,36(7):1098-1101.
    [9] Arimura Y, Yano T, Hirano M, et al. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis[J]. Free Radic Biol Med, 2012,52(9):1865-1873.
    [10] Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 1996,40(10):2428-2430.
    [11] Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods[J]. J Antimicrob Chemother, 2003,51(4):857-864.
    [12] Singh SR, Bacon AR, Young DC, et al. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2009,53(10):4495-4497.
    [13] Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003,47(9):3002-3004.
    [14] Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections:meta-analysis of randomised controlled trials[J]. Int J Antimicrob Agents, 2010,35(1):3-12.
    [15] 穆玉, 范春芳, 朱铁梁, 等. 重症患者利奈唑胺所致血小板减少危险因素分析[J]. 中国感染与化疗杂志, 2012,12(1):10-14.
    [16] Kalil AC, Metersky ML, Klompas M, et al. Executive summary:management of adults with hospital-acquired and ventilator-associated pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016,63(5):575-582.
    [17] Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia:an antibiotic pharmacodynamic analysis[J]. J Antimicrob Chemother, 2003,52(4):668-674.
    [18] Kato H, Hagihara M, Hirai J, et al. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen[J]. Drugs RD, 2017,17(1):177-187.
    [19] Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients[J]. Crit Care, 2013,17(4):R165.
    [20] 付双双, 唐惠林, 段京莉. 抗感染药物治疗药物监测的Meta分析[J]. 中国新药杂志, 2013,22(15):1840-1848.
    [21] 梅清, 喻婷, 朱玉林, 等. 万古霉素单用及联合利福平或磷霉素对耐甲氧西林金黄色葡萄球菌防耐药突变浓度的研究[J]. 中国药理学通报, 2011,27(7):944-947.
    [22] 胡文, 邓国泉, 伍婷, 等. 万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J]. 实用中西医结合临床, 2012,12(4):6-7.
    [23] 中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组. 雾化吸入疗法在呼吸疾病中的应用专家共识[J]. 中华医学杂志, 2016,96(34):2696-2708.
  • [1] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [2] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202306040
    [3] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [4] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [5] 徐飞, 陈瑾, 鲁育含, 李志勇.  肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
    [6] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
  • 加载中
计量
  • 文章访问数:  2732
  • HTML全文浏览量:  347
  • PDF下载量:  622
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-01-19
  • 修回日期:  2017-06-12

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

摘要: 目的 探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。 方法 临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗,通过分析其病理生理状况,运用治疗药物监测,协助临床医生制订个体化的给药方案。 结果 患者初始抗感染治疗方案效果不佳,临床药师根据患者的个体情况和血药浓度监测结果调整给药方案,患者的感染得到控制,病情好转。 结论 确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。

English Abstract

石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
引用本文: 石晓萍, 吕迁洲, 杨婉花, 方洁. 1例重症患者抗感染个体化给药策略分析[J]. 药学实践与服务, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
Citation: SHI Xiaoping, LYU Qianzhou, YANG Wanhua, FANG Jie. The individualized anti-infective treatment strategy for a critically ill patient[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(6): 554-558. doi: 10.3969/j.issn.1006-0111.2017.06.018
参考文献 (23)

目录

    /

    返回文章
    返回